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Familial Hyperinsulinism due to HNF4A Deficiency and Benign 
Premature Adrenarche: A Case Report 
Edward Compton,1 David H. Geller,2 Alaina P. Vidmar MD.3 
Abstract 
Background: Familial Hyperinsulinism due to HNF4A deficiency (FHI-HNF4A) is a form of diazoxide-sensitive, diffuse hyperinsulinism, characterized by 
transient or persistent hyperinsulinemic hypoglycemia, and a propensity to develop Maturity-Onset Diabetes of the Young type 1 (MODY1). The association 
between FHI-HNF4A deficiency and benign premature adrenarche (BPA) is unknown. The Case: We report the case of a 5-year-old girl with FHI-HNF4A, 
controlled on diazoxide, who presented with BPA and Tanner stage 3 pubic hair associated with body odor and acne. Work-up revealed elevated 
dehydroepiandrosterone sulfate (DHEAS), elevated free testosterone, and advanced bone age. Insulin levels were elevated in the setting of normal fasting 
blood glucose. We discuss the possible hormonal underpinnings of hyperandrogenism. Conclusion: Though the underlying pathophysiology of this 
phenotype is unclear, a possible synergistic mechanism exists between insulin-induced hyperandrogenism and HNF4A deficiency leading to a transient 
decrease of SHBG and thus increased free testosterone levels. Further investigation is required to determine the association between HNF4A dysfunction 
and BPA. 
 




Congenital hyperinsulinism (CHI) is due to a variety of etiologies that 
result in dysregulated insulin release from pancreatic β-cells. There are 
two histological variants of CHI, focal and diffuse, which differ in the 
extent of pancreatic involvement. In the diffuse variant, all of the β-
cells are affected, while in the focal form, a localizable lesion is found, 
affecting only a subset of the β-cells.1 Insulin secretion uncoupled from 
glucose metabolism results in hyperinsulinemic hypoglycemia.2,3 
Familial Hyperinsulinism due to HNF4A deficiency (FHI-HNF4A) is a form 
of diazoxide-sensitive, diffuse hyperinsulinism, characterized by 
macrosomia, transient or persistent hyperinsulinemic hypoglycemia, 
and a propensity to develop Maturity-Onset Diabetes of the Young type 
1 (MODY1). Patients with FHI-HNF4A are responsive to diazoxide 
treatment, which activates KATP channels, leading to increased 
potassium conductance, cellular membrane hyperpolarization, and 
inhibition of insulin release.4,5 Patients with CHI due to other genetic 
variants, in which the mutation lies within subunits of the KATP channels 
themselves, are not responsive to diazoxide treatment.6 The role of 
HNF4A in FHI-HNF4A has yet to be fully elucidated, but it is thought to 
work in combination with other transcription factors, forming a 
regulatory network of proteins in the pancreatic islet.7 Mechanistically, 
HNF4A deficiency can impair the binding of HNF4A with p300, which 
then prevents HNF4A from binding to the promoter region of HNF1. 
Interestingly, there is a growing body of evidence that mRNA levels of 
HNF4A correlate with Sex Hormone Binding Globulin (SHBG) mRNA 
levels. Therefore, HNF4A deficiency may result in decreased SHBG, with 
subsequent increased levels of free testosterone.8 The clinical 
consequence of this process is poorly understood.  
 
Benign premature adrenarche (BPA) is a clinical diagnosis often 
associated with elevations of dehydroepiandrosterone (DHEA) and 
dehydroepiandrosterone sulfate (DHEAS) for chronological age,.9,10 If 
phenotypic signs of androgen activity, such as pubic and/or axillary 
hair, adult-type body odor, oily skin or hair, comedones, or accelerated 
growth velocity, are detected before the age of  8  in  females  or  9  in 
 
 
increased rates of obesity in children with BPA.9,10 However, other 
conditions that present similarly must first be excluded before BPA can 
be diagnosed. These include: central puberty, adrenocortical and 
gonadal sex-hormone secreting tumors, congenital adrenal hyperplasia, 
and exposure to exogenous androgens. In some populations, BPA has 
been associated with low birth weight, insulin resistance, adverse 
cardiometabolic risk, and progression to polycystic ovary syndrome 
(PCOS).11-15 Herein, we report a 5-year-old female patient with FHI-HNF4A 
who presented with BPA in the setting of elevated insulin level, despite 
euglycemia on diazoxide therapy. The underlying pathophysiology of 
Highlights: 
 Familial Hyperinsulinism due to HNF4A deficiency (FHI-HNF4A) is a 
form of diazoxide-sensitive; diffuse hyperinsulinism, characterized by 
transient or persistent hyperinsulinemic hypoglycemia, and 
subsequent propensity to develop MODY1. 
 By altering the HPA and HPG axes, hyperinsulinism may lead to 
increased levels of circulating androgens, which has been 
demonstrated in conditions with insulin resistance and subsequent 
hyperinsulinism, such as polycystic ovary syndrome (PCOS).  
 Regulation of HNF4A by many factors indirectly regulates hepatic SHBG 
synthesis, as HNF4A plays an imperative role in the regulation of 
SHBG.  
 The association of elevated insulin levels, insulin resistance, and 
functional hyperandrogenism has been previously described in youth 
with benign premature adrenarche (BPA) and polycystic ovarian 
syndrome (PCOS) however there have been no reports in a patient 
with FHI-HNF4A. 
 These findings may suggest that patients with FFI-HNF4A may be at 
greater risk for insulin induced hyperandrogenism and therefore 
diazoxide dosage should be titrated to insulin levels to prevent 
functional hyperandrogenism and its sequelae.  
 If HNF4A defects play a role in altering SHBG levels, it may be clinically 
relevant to screen patients with BPA for these alterations.  
Case Report  
 
Compton E, et al. Familial Hyperinsulinism due to HNF4A Deficiency and Benign Premature Adrenarche: A Case Report
 
 
Int J Med Students   •   2021  |  May-Jun  |  Vol  9  |  Issue 2 
                             DOI 10.5195/ijms.2021.721  |  ijms.info The International Journal of Medical Students 168
 
this phenotype remains obscure; however, we discuss a possible 
synergistic mechanism between insulin-induced hyperandrogenism 
and HNF4A deficiency, leading to transient decrease of SHBG and thus 
increased free testosterone levels. 
 
The Case 
A 5-year-old girl with known FHI-HNF4A, who was first noted by her 
mother to have new-onset acne and body odor without any associated 
breast changes, pubic hair, or menses at 4 years of age, presented to 
the pediatric endocrinology clinic for follow-up. Her pubic hair had 
progressed to Tanner stage 3 with increased acne and body odor. No 
exogenous steroid exposures were reported. Physical exam revealed 
Tanner stage 1 breasts. Laboratory testing revealed abnormalities in the 
following: free testosterone 0.6 ng/dL (normal range < 0.04-0.14 ng/dL), 
and DHEAS 146 mcg/dL (normal range: ≤ 34 mcg/dL). The following were 
within reference ranges: fasting laboratory testing revealed a HbA1c of 
4.0% (normal range: 3.0-5.8%), a fasting blood glucose of 80 mg/dL 
(normal range: 70-100 mg/dL), anti-Mullerian hormone 1.3 ng/mL, 
estradiol < 7 pg/mL (normal range: < 7 pg/mL), total testosterone < 7 
ng/dL (normal range: <7-20 ng/dL),  insulin 11.3 uIU/mL (normal range: 
2.0-19.6 uIU/mL), 17-hydroxypregnenolone 177 ng/dL (normal range: ≤ 
561 ng/dL), 17-hydoxyprogesterone 35 ng/dL (normal range: ≤ 137 
ng/dL), serum androstenedione 18 ng/dL (normal range : ≤ 45 ng/dL  and 
serum DHEA 159 ng/dL (normal range: ≤ 487 ng/dL) (Table 1). A bone 
age study revealed an advanced bone age of 7.8 years and at this time, 
the decision was made to monitor the patient serially, without altering 
diazoxide dosing. 
 
Table 1. Clinical and laboratory findings at most recent visit. 
 
Characteristics Patient Values 
Reference Range (if 
applicable) 
Age, years 6.0 
 
Bone age, years 7.8 
 
Weight, kg (%ile) 17.3 (15) 
 
Height (%ile) 110.7 (27) 
 






Glucose, mg/dL 80 60-115 
HbA1c 4.3 3.0-6.0 
Anti-Mullerian Hormone 1.3 
 
 
Estradiol, pg/mL < 7 <7 
Total Testosterone, ng/dL < 7 < 7 
Insulin, uIU/mL 11.3 2.0-19.6 
17-hydroxyprogesterone, 
ng/dL 
35 ≤ 137 
17-hydroxypregnenolone, 
ng/dL 
177 ≤ 561 
Serum androstenedione, 
ng/dL 
18 ≤ 45 
DHEA sulfate, mcg/dL 146 ≤ 34 
DHEA, ng/dL 159 ≤ 487 
 
Legend: BMI = body mass index; DHEA = Dehydroepiandrosterone 
 
The patient’s past medical history was significant for premature 
delivery at 34 weeks gestation due to premature rupture of membranes. 
The vaginal delivery was complicated by prolonged labor and fetal 
distress. Her birth weight was 1870 grams, with an associated length of 
43.15 cm, appropriate for gestational age. She had a macrosomic 
appearance at birth. She was admitted to the neonatal intensive care 
unit for fifty days, requiring supplemental oxygen for twelve days. She 
was found to have persistent hypoglycemia, requiring a glucose 
infusion rate of 18-20 mg/kg/minute. She was diagnosed with 
hyperinsulinemic hypoglycemia on day five of life and was started on 
diazoxide at 15 mg/kg/day. Subsequent laboratory and genetic testing 
confirmed her heterozygous HNF4A mutation (NM_00457.4 c.253C>T, 
p.Arg85trp – PubMed. 2030154, OMIM. 6160266), pathogenic for FHI-
HNF4A. By the age of 2, she was taking 100% of her caloric needs orally, 
requiring gastrostomy tube (G-tube) supplementation only during times 
of illness. Her blood glucose levels were within the target range 90% of 
the day based on continuous glucose monitoring data and her HbA1c 
was 4.5%. Her father was diagnosed with FHI-HNF4A in infancy; at the 
age of 20, was found to have hyperglycemia consistent with MODY1. 
 
The family was lost to follow up and presented for referral to the 
pediatric endocrinology clinic for consultation and management of 
congenital hyperinsulinism when she was 2.5 years old. At this time, 
she weighed 10.5 kg (< 3rd percentile), with a height of 87.5 cm (10th 
percentile) and BMI of 13.71 kg/m2 (< 3rd percentile). On physical exam, 
she had numerous dysmorphic features including macrosomia, down-
turned palpebral fissures, broad midface, low-set ears, and broad, 
wide-set thumbs. She had diffuse hypertrichosis of the arms, face, 
back, and abdomen. Her external genitalia were normal for age, with 
Tanner stage 1 axillary and pubic hair, and breasts with Tanner stage 1 
development. At this time, blood glucose levels were being monitored 
only once daily, and it was recommended that blood glucose checks be 
increased to 6 times daily to ensure that cryptic hypoglycemia was 
detected, as HbA1c was < 4.0%. She was placed on an iPro glucose 
monitor (CGM) to collect continuous glucose levels for 96 hours, which 
demonstrated hypoglycemia 20% of the time. She was maintained on 
diazoxide at 12 mg/kg/day divided three times daily (TID). Due to 
concern for poor annualized growth velocity of 1.4 cm/year, a bone age 
was obtained, which showed skeletal age concordant with 
chronological age. 
 
At a subsequent follow-up at 3.5 years old, her HbA1c was 4.0%, with 
weight gain and associated increased annualized growth velocity of 6 
cm/yr. Continuous glucose monitoring was recommended to detect 
overnight hypoglycemic episodes, but the patient’s family declined this 
option. She was receiving feeding therapy and her oral intake had 
improved significantly. Although she no longer utilized G-tube feedings, 
she was having multiple episodes of hypoglycemia overnight.  Her 
diazoxide dose was increased to 13 mg/kg/day divided TID, with 
resolution of her overnight hypoglycemia. 
 
Discussion 
We report a unique case of a 5-year-old female with FHI-HNF4A who 
presented with Tanner 3 pubic hair, acne, body odor, elevated DHEAS 
and free testosterone, and advanced bone age in the absence of 
elevated estradiol levels. Her presentation is most consistent with BPA; 
however, the relationship between FHI-HNF4A and BPA remains poorly 
understood. Although the BMI percentile of our patient was 18%, prior 
studies have found an association between BPA and obesity.9,10 There 
is a wide differential diagnosis for patients that are found to be 
persistently hypoglycemic after birth, including hyperinsulinism as in 
our patient, mutations in enzymes involved in fatty acid metabolism, 
glycogen storage disorders, counter-regulatory hormone deficiencies. 
While the differential is broad, we suspected hyperinsulinemia as the 
culprit in our patient, given her father’s diagnosis of FHI in infancy. 
Thus, genetic testing was obtained early in her disease course. Many 
of the etiologies of persistent hypoglycemia in infancy involve a genetic 
component, highlighting the importance of obtaining a satisfactory 
family history, as this can help narrow the differential diagnosis, 
expediting achieving a diagnosis.   
 
Besides HNF4A, other genes have been implicated in hyperinsulinemia, 
with the two most common being mutations in ABCC8 and KCNJ11. 
Mutations in these two genetic loci are responsible for both focal and 
diffuse forms of CHI, leading to vastly different treatments and 
outcomes. Therefore, genetic analysis becomes important for 
counseling families on treatment and prognosis, as one study 
demonstrated that detecting a single paternally derived mutation 
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One possible mechanism to explain the observed association is that 
our patient was experiencing transient hyperinsulinism resulting in 
increased adrenal androgen production. Insulin is hypothesized to play 
a role in the regulation of the hypothalamic-pituitary-adrenal (HPA) and 
hypothalamic-pituitary-gonadal (HPG) axes.17,18 A variety of regulatory 
mechanisms have been proposed, including altered expression of key 
enzymes involved in steroidogenesis, increased secretion of 
gonadotropin-releasing hormone (GnRH), increased amplitude of 
luteinizing hormone (LH) pulses, potentiation of ACTH-stimulated 
steroidogenesis, and inhibition of SHBG production.8 By up-regulating 
one or both of the HPA and HPG axes, hyperinsulinism may lead to 
increased levels of circulating androgens. In patients with conditions 
such as PCOS, which have been associated with BPA, elevated total and 
free androgens have been demonstrated in the setting of insulin 
resistance and decreased SHBG.19,20 However, prior studies have not 
explored the potential relationship between FHI-HNF4A or other genetic 
CHI disorders, and BPA. Mechanistically, insulin has been demonstrated 
to increase mRNA levels of CYP17A1 and 3-HSD and potentiate ACTH 
production of intermediates involved in DHEAS synthesis, leading 
authors to conclude that the hyperandrogenic features observed in 
PCOS may be due in part to a hyperinsulinemia-derived increase in 
adrenal androgens.21,22 
 
Ibanez et al. studied 10 non-obese adolescent females who had 
experienced BPA, hirsutism, ovarian hyperandrogenism, 
oligomenorrhea, dyslipidemia, and hyperinsulinemia. These females 
were administered metformin daily for 6 months, which reduced insulin 
levels, hirsutism, and hyperandrogenism, and attenuated the release 
of LH in response to GnRH pulses. One of the mechanisms by which 
metformin improves hyperglycemia in diabetes is through the inhibition 
of mitochondrial glycerophosphate dehydrogenase, which inhibits 
gluconeogenesis and increases insulin sensitivity, thereby decreasing 
insulin requirements. Metformin administration also increases SHBG, 
leading to decreased serum-free androgens.23,24 Importantly, the 
authors noted that DHEAS decreased with metformin, buttressing the 
argument that insulin increased adrenal androgen production.23 In a 
study contrasting 47 adolescent females with BPA vs 22 healthy female 
controls, Kaya et al. found that females with BPA had higher body mass 
indexes and insulin concentrations.10 These females also had hyper-
responsiveness to ACTH, leading to increased androstenedione and 
DHEA levels. This study further elucidates the unique role insulin plays 
in the regulation of adrenal sex hormone production.  
 
An additional mechanism to consider in this patient is the effect of 
HNF4A function on SHBG levels. Hammond et al. proposed that 
activation of the SHBG promoter in the liver involves HFN4 binding to a 
DR1-like cis-element which then stimulates production.25 Therefore, in 
HNF4A deficiency, SHBG production would be decreased, with 
consequent increases in free androgen levels. Winters et al. found a 
strong positive correlation between the level of HNF4A mRNA and SHBG 
mRNA, with an inverse relationship between insulin resistance/insulin 
levels, and circulating SHBG and HNF4A mRNA levels.26 These findings 
suggest that circulating SHBG levels may be mediated by HNF4A and 
provide further insight into the mechanism by which HNF4A deficiency 
could predispose a patient with FHI-HNF4A to BPA. The combination of 
these two molecular entities could have resulted in the BPA-like 
phenotype observed in our patient. A summary of the proposed 
mechanisms of insulin regulation of androgen synthesis and circulatory 
levels is shown in Figure 1.  
 
 
Figure 1. Proposed mechanisms of insulin regulation of androgen synthesis 
and circulatory levels. 
 
 
Legend: 3B-HSD = 3-hydroxysteroid dehydrogenase; ACTH = Adrenocorticotropic hormone; 
CYP17A1 = cytochrome P450 17A1; DHEAS = dehydroepiandrosterone sulfate; GnRH = 
gonadotropin releasing hormone; IGF = insulin-like growth factor; IGFBP-1 = insulin-like growth 
factor binding protein 1; LH = luteinizing hormone; SHBP = sex hormone binding protein. 
 
This case demonstrates that clinically silent hypoglycemia with 
concomitant intermittent hyperinsulinemia may have long-term 
sequelae for the patient. Therefore, even if glycemic control is adequate 
overall, with HbA1c levels within normal limits, it is important not to 
ignore either glucose levels or HbA1c levels that are down-trending. 
Large fluctuations in blood glucose levels should be avoided, with close 
monitoring of daily glucose checks. In our patient, glucose checks were 
only being performed once daily; subsequent continuous glucose 
monitoring demonstrated hypoglycemia 20% of the time. This highlights 
the importance of more rigorous glucose monitoring in these patients, 
as they may not present with the normal signs of hypoglycemia 
(diaphoresis, lightheadedness, tachycardia, etc.) and thus their 
hypoglycemia may go clinically undetected until more severe sequela 
develops. This has important treatment implications, as tight medical 
management becomes paramount. While our patient responded well 
and tolerated diazoxide, other patients may not respond as well, 
requiring additional treatment considerations to adequately control 
glucose, and subsequently, insulin levels.  
 
We believe that our patient may have been experiencing episodes of 
hypoglycemia, as evidenced by her HbA1C levels on the low end of 
normal. Episodes of hypoglycemia may have been due to intermittent 
hyperinsulinemia in spite of diazoxide treatment. We hypothesize these 
periods of hyperinsulinemia may have been sufficient to increase 
adrenal steroidogenic activity, and subsequently, increased circulating 
levels of DHEAS. Furthermore, her HNF4A deficiency may have led to a 
decrease in SHBG levels resulting in elevated free testosterone. Future 
studies are needed to 1) investigate the underlying molecular etiology 
of hyperandrogenism in patients with FHI-HNF4A and BPA, 2) elucidate 
the optimal dosage of diazoxide treatment in FHI-HNF4A to prevent any 
long-term sequelae that could occur in the setting of transient 
hyperinsulinemia, and 3) explore the relationship between HNF4A 
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